Trials / Completed
CompletedNCT00788931
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
A Phase Ib, Open-label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IV LBH589 | |
| DRUG | Oral LBH589 | |
| DRUG | trastuzumab | |
| DRUG | paclitaxel |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2010-08-01
- First posted
- 2008-11-11
- Last updated
- 2020-12-19
Locations
7 sites across 5 countries: United States, Australia, Belgium, Italy, Netherlands
Source: ClinicalTrials.gov record NCT00788931. Inclusion in this directory is not an endorsement.